ASX-listed global biosensor company Universal Biosensors (ASX:UBI) reports work conducted on its Tn Antigen cancer biosensor has been published in the American Chemical Society Journal “ACS Sensors” and has been presented on the front cover of the publication.
The cancer biosensor was published within the new journal article titled “A Rapid Point-of-Care Electrochemical Sensor for the Detection of Cancer Tn Antigen Carbohydrate in Whole Unprocessed Blood,” and reports the results of the first development clinical study of the Tn Antigen biosensor.
The clinical study was performed on whole blood and retrospective blood plasma samples collected from healthy and real patients currently suffering from prostate, colorectal and breast cancers, as well as in collaboration with the Peter MacCallum Cancer Centre.
The development clinical study was undertaken by researchers from Swinburne University of Technology and Deakin University in conjunction with scientists from Universal Biosensors.
Addressing the publishing of the company’s cancer biosensor, Universal Biosensors CEO, John Sharman said: “The publication of this work in such an esteemed scientific peer reviewed journal is a ‘significant’ endorsement for the technology. Our ambition is to create a biosensor capable of mapping and measuring changes to a cancer patients’ tumour in a point-of-care setting.
“The publication of this work in such an esteemed scientific peer reviewed journal is a ‘significant’ endorsement for the technology.”
UBI’s recent focus has been on the manufacturing process for the Tn Antigen cancer biosensors with the aim to create a reliable and reproducible biosensor which can be manufactured in high volumes. We continue to develop the biosensor test strip and our next series of development studies will commence once the next generation of biosensor test strips are complete. Our Tn Antigen cancer biosensor project remains broadly on track and within our projected timelines and budgets.”
ACS Sensors is a widely recognised leading academic journal within the medical field and specialises in new and innovative breakthroughs on the front-lines of sensor and diagnostic technologies.
As of 2:30pm (AEST) Universal Biosensors’ share price has increased by 10.63%.
Universal Biosensors is a global biosensor company and world leader in electrochemical cell technology, with an ambition to utilise its patented biosensor technology to develop a diverse range of biosensor test strips used in its hand-held portable analysers; for cost effective, effortless and accurate detection of analytes of interest.
The company’s Tn Antigen biosensor is built upon a novel anti-fouling technology based on lubricin, a biological lubricant and anti-adhesive protein that naturally occurs in the body which is reported to ‘significantly’ improve the electrochemical signals and detection limits in electrochemical sensors within highly fouling biological fluids.
The publication comes following a rigorous international scientific peer-reviewed process of the work undertaken on the Tn Antigen biosensor.
Images: Universal Biosensors, Inc
